---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Special populations"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Special populations. Topics: Adolescents aged 12 to 17 years: eligibility and enrollment in the phase 3 trial, Children younger than 12 years: EU paediatric investigation plan, Older adults: upper age limit and participants aged 65 years or older in the phase 3 trial, Older adults: age limit of the phase 1 concentration-QTc population, and 5 further topics. 9 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/special-populations"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Special populations

<a id="heading-2.1.2.8"></a>

## 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

### Adolescents aged 12 to 17 years: eligibility and enrollment in the phase 3 trial

> “For adolescent participants aged ≥12 and”
> “18 years of age: body weight ≥40 kg.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

> “134 eligible participants (ten [7%] adolescents and 124 [93%] adults) were randomly allocated.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.8-2"></a>

### Children younger than 12 years: EU paediatric investigation plan

> “Age appropriate oral solid dosage form”
> “Capsule, soft”
> “Prolonged-release tablet”
> “Treatment of hereditary angioedema”
> “EMA/PE/0000227462 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for deucrictibant monohydrate”

Source: [EMA paediatric investigation plan modification EMA/PE/0000227462 (2025)](https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000227462)

<a id="topic-2.1.2.8-3"></a>

### Older adults: upper age limit and participants aged 65 years or older in the phase 3 trial

> “Male or female, aged ≥12 to ≤75 years at the time of providing written informed consent/assent.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

| Age group | RAPIDe-3 enrolled participants (N = 134), n (%) |
| --- | --- |
| Aged 12 to younger than 18 years | “10 (7.5)” |
| Aged 18 to younger than 65 years | “116 (86.6)” |
| Aged 65 years or older | “8 (6.0)” |

Source: [Riedl et al. (2026a)](https://ir.pharvaris.com/static-files/39c3dc39-68f9-4cd9-b814-63bddfe7255b)

<a id="topic-2.1.2.8-4"></a>

### Older adults: age limit of the phase 1 concentration-QTc population

> “Eligible participants: healthy male and female participants (of non-childbearing potential), between 18 and 65 years of age (inclusive) with a body mass index between 18.0 and 30.0 kg/m2 (inclusive).”

Source: [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853)

<a id="topic-2.1.2.8-5"></a>

### Pregnancy and lactation: exclusion from the on-demand trials

> “As reproductive and developmental toxicity studies were not available for deucrictibant and potential effects of deucrictibant on the fetus were unknown, pregnant and breastfeeding women were not eligible. Women and male partners of women of childbearing potential were eligible if sexually abstinent or using medically acceptable contraception.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Pregnant and breastfeeding women were not eligible. Women of childbearing potential were eligible if sexually abstinent or using medically acceptable contraception.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.8-6"></a>

### Pregnancy and fertility: nonclinical reproductive studies

> “Deucrictibant has not demonstrated any adverse effects on embryo-fetal survival and development in the humanized bradykinin B2 receptor transgenic rat or in the rabbit. Furthermore, male and female fertility studies showed no adverse effects of deucrictibant on gonadal function, mating behavior, and reproductive performance.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.8-7"></a>

### Hepatic impairment: dedicated pharmacokinetic study and exclusion from the on-demand trials

> “Hepatic impairment”
> “Open-label, single dose to assess the effect of hepatic impairment on pharmacokinetics”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “Patients were excluded in cases of abnormal hepatic or renal function”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Abnormal hepatic function.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-2.1.2.8-8"></a>

### Renal impairment: dedicated pharmacokinetic study and exclusion from the phase 3 trial

> “Renal impairment”
> “Open-label, single dose to assess the effect of renal impairment on pharmacokinetics”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “Abnormal renal function (eGFR”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-2.1.2.8-9"></a>

### Japanese, Chinese, and Caucasian participants: extended-release tablet multi-ethnicity study

> “XR multi-ethnicity study”
> “Open-label, multiple dose study to compare PK of extended-release formulation between healthy Japanese, Chinese, and Caucasian volunteers”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
